Going Early For Maximum Long Term Value From Medtech Deals

For Medtech Deal-Makers The Best Opportunities Must Be Developed Well In Advance Of M&A

22 Feb 2022

Strategics pursuing high growth M&A plays are often ready to pay a premium price for a target. But with medtech valuations at historic highs, they cannot afford to do that every time. One solution is to take a strategic stake and build early, according to an AdvaMed panel hosted by EY’s John Babitt.

“I would never have thought 2021 would turn out as it did,” said John Babitt, a Minneapolis-based partner with EY. He was referring to the uncharted heights achieved last year in medtech M&A deal-making and venture capital funding.

For 2021 as a whole, $111bn was paid out on 64 medtech M&A deals. Both of these were record numbers,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Wide Of The Mark: ‘The Worst EU Medtech Predictions Have Not Come True’

19 Jun 2025

• By Ashley Yeo

Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

18 Jun 2025

• By Jo Shorthouse

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist